@article{fdi:010063632,
  title = {{E}fficacy of artesunate-amodiaquine for the treatment of acute uncomplicated falciparum malaria in southern {M}auritania},
  author = {{O}uldabdallahi, {M}. and {A}lew, {I}. and {O}uld {A}hmedou {S}alem, {M}. {S}. and {B}a, {D}. {M}. and {O}uld {M}ohamed {S}alem {B}oukhary, {A}. and {O}uld {K}hairy, {M}. {L}. and {A}ziz, {M}. {B}. {A}. and {R}ingwald, {P}. and {B}asco, {L}eonardo and {N}iang, {S}. {D}. and {L}ebatt, {S}. {M}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {A} regular evaluation of therapeutic efficacy in sentinel sites and a system of surveillance are required to establish treatment guidelines and adapt national anti-malarial drug policy to the rapidly changing epidemiology of drug-resistant malaria. {T}he current anti-malarial treatment guideline in {M}auritania, officially recommended since 2006, is based on artemisinin-based combination therapy. {T}he aim of the present study was to evaluate clinical efficacy and tolerance of artesunate-amodiaquine, the first-line treatment for acute uncomplicated malaria, in {M}auritanian paediatric and adult patients to validate its continued use in the country. {M}ethods: {P}lasmodium falciparum-infected symptomatic patients aged > six months were enrolled in {K}obeni and {T}imbedra in southern {M}auritania in {S}eptember to {O}ctober 2013. {C}o-formulated artesunate-amodiaquine was administered at the recommended dose over three days. {P}atients were followed until day 28. {P}arasitological and clinical response was classified according to the standard 2009 {W}orld {H}ealth {O}rganization protocol. {R}esults: {A} total of 130 patients (65 in {K}obeni and 65 in {T}imbedra) were enrolled in the study. {S}eventeen patients (13.1%) were either excluded (before {PCR} correction) or lost to follow-up. {B}ased on the per protocol analysis, artesunate-amodiaquine efficacy (i.e., the proportion of adequate clinical and parasitological response) was 96.6% in {K}obeni and 98.2% in {T}imbedra before {PCR} correction. {L}ate clinical failure was observed in two patients in {K}obeni and one patient in {T}imbedra. {A}fter {PCR} correction, the efficacy rate in the two study sites was 98.2%. {O}n day 3, all patients were afebrile and had negative smears. {T}reatment was well tolerated. {C}onclusions: {A}rtesunate-amodiaquine is well tolerated and highly efficacious for the treatment of uncomplicated {P}. falciparum malaria. {I}n the majority of patients, fever and parasitaemia were rapidly cleared before day 3. {T}he results support the national anti-malarial drug guideline for a continued use of artesunate-amodiaquine as a first-line drug for uncomplicated malaria in southern {M}auritania.},
  keywords = {{D}rug resistance ; {P}lasmodium falciparum ; {A}rtemisinin ; 4-aminoquinolines ; {C}linical trial ; {MAURITANIE}},
  booktitle = {},
  journal = {{M}alaria {J}ournal},
  volume = {13},
  numero = {},
  pages = {art. 496 [6 p.]},
  ISSN = {1475-2875},
  year = {2014},
  DOI = {10.1186/1475-2875-13-496},
  URL = {https://www.documentation.ird.fr/hor/fdi:010063632},
}